Wu, Qian
Zhang, Xueqing
Li, Hui
Tang, Lirui
Zeng, Yibin
Lin, Jing
Chen, Yu
Li, Jinluan http://orcid.org/0000-0002-3533-898X
Funding for this research was provided by:
Fujian Research and Training Grants for Youth and Middle-aged Leaders in Healthcare (2022)
Joint Funds for the innovation of science and Technology, Fujian province (2021Y9202)
National Clinical Key Specialty Construction Program (2021)
Fujian Provincial Clinical Research Center for Cancer Radiotherapy and Immunotherapy (2020Y2012)
Article History
Received: 20 March 2023
Accepted: 8 June 2023
First Online: 29 June 2023
Declarations
:
: This is a retrospective study and which was conducted in accordance with the 1964 Declaration of Helsinki and International Conference on Harmonization of Good Clinical Practice Tripartite guidelines. This clinical study was approved by the Ethics Committee of Fujian Cancer Hospital Fuzhou, China (No. K2023-030-01). All patients gave informed consent to participate in this study.
: This was a retrospective clinical study. The present study was approved by the ethics committee of Fujian Cancer Hospital (No. K2023-030-01), and patients included from this hospital had signed the informed consent for clinical data research before treatment.
: The authors have no relevant financial or non-financial interests to disclose.